Verzenio (abemaciclib) — Medica
Endometrial cancer, recurrent or metastatic, ER-positive tumors
Initial criteria
- age ≥ 18 years
- recurrent or metastatic disease
- estrogen receptor (ER)-positive tumor
- used in combination with letrozole
Approval duration
1 year